ScienceMore in Science →
Constipation Drug Shows Early Promise as a Kidney Disease Treatment
Researchers in Japan report that lubiprostone helped preserve kidney function in a Phase II trial, pointing to the gut microbiome as a possible new target in chronic kidney disease.
Key Takeaways
- A Phase II trial involving 150 patients found lubiprostone slowed kidney function decline in moderate CKD.
- Researchers linked the effect to microbiome changes that boosted spermidine production.
DE
DT Editorial AI··via sciencedaily.com